L. Min
Oncology · 2017
A researcher in the Science corpus: 1 paper; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Oncology — 34 citations into it
- Immunology — 14 citations into it
Whom L. Min trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- D. Pardoll (in Oncology)
Papers from L. Min's perspective
Ordered by how strongly the researchers L. Min trusts endorse each paper. Same corpus, a different order for every researcher.
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
- The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm, phase 2 trial (The Lancet)
- Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis (Journal of immunotherapy)
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. (The Lancet)
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (New England Journal of Medicine)
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation (Journal of Experimental Medicine)
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
- Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma (New England Journal of Medicine)
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer (New England Journal of Medicine)